Skip Navigation

This Article
Right arrow Abstract Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Disclaimer
Right arrow Request Permissions
Google Scholar
Right arrow Articles by McMurray, J.J.V
Right arrow Articles by Stewart, S
Right arrow Search for Related Content
PubMed
Right arrow Articles by McMurray, J.J.V
Right arrow Articles by Stewart, S
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?


The burden of heart failure

J.J.V McMurray*,1 and S Stewart2

a CRI in Heart Failure, Wolfson Building, University of Glasgow, Glasgow, U.K.
b School of Nursing and Midwifery, Division of Health Sciences, University of South Australia, Adelaide, Australia

* Correspondence: John J. V. McMurray, Professor of Medical Cardiology, CRT in Heart Failure, Wolfson Building, University of Glasgow, G12 8QQ, U.K.

Abstract

Chronic heart failure (CHF) places a heavy burden not only on patients and their families but also on society, through enormous use of health care resources. CHF has an overall population prevalence of approximately 1–3%, rising to approximately 10% in the very elderly. Following a first hospital admission for heart failure, patients have a 5-year mortality of 75% — a survival rate worse than that for most forms of cancer. CHF impairs quality of life more than almost any other chronic medical problem. Hospital admissions for CHF have increased markedly over the past two decades. CHF accounts for about 5% of all medical admissions and approximately 2% of total health care expenditure. Despite improvements in medical management, under-treatment is common. Because of the increase in survival after acute myocardial infarction and ageing of the population, the number of patients with CHF will increase rapidly in most industrialized countries. CHF will still pose one of the greatest health care challenges of the 21 st century.

Key Words: Epidemiology • health economics • heart failure • incidence • prevalence

References

  1. McMurray JJ, Petrie MC, Murdoch DR, Davie AP. Clinical epidemiology of heart failure: public and private health burden. Eur Heart J. 1998;19(suppl P):P9–P16
  2. McMurray JJ, Stewart S. Epidemiology, aetiology, and prognosis of heart failure. Heart. 2000;83:596–602[Free Full Text]
  3. Petrie M, McMurray J. Changes in notions about heart failure. Lancet. 2001;358:432–434[CrossRef][Web of Science][Medline]
  4. Murdoch DR, McMurray JJV. Epidemiological perspective on heart failure: common, costly, disabling, deadly. Sharpe N. Heart Failure Management 2000. London: Martin Dunitz; 1999.
  5. Ho KK, Pinsky JL, Kannel WB, Levy D. The epidemiology of heart failure: the Framingham Study. J Am Coll Cardiol. 1993;22(suppl A):6A–13A
  6. Schocken DD, Arrieta MI, Leaverton PE, Ross EA. Prevalence and mortality rate of congestive heart failure in the United States. J Am Coll Cardioi. 1992;20:301–306[Abstract]
  7. Eriksson H, Svardsudd K, Larsson B, et al. Risk factors for heart failure in the general population: the study of men born in 1913. Eur Heart J. 1989;10:647–656[Abstract/Free Full Text]
  8. Clarke KW, Gray D, Hampton JR. How common is heart failure? Evidence from PACT (Prescribing Analysis and Cost) data in Nottingham. J Public Health Med. 1995;17:459–464[Abstract/Free Full Text]
  9. Cowie MR, Wood DA, Coats AJ, et al. Incidence and aetiology of heart failure; a population-based study. Eur Heart J. 1999;20:421–428[Abstract/Free Full Text]
  10. Remes J, Reunanen A, Aromaa A, Pyorälä K. Incidence of heart failure in eastern Finland: a population-based surveillance study. Eur Heart J. 1992;13:588–593[Abstract/Free Full Text]
  11. McDonagh TA, Morrison CE, Lawrence A, et al. Symptomatic and asymptomatic left-ventricular systolic dysfunction in an urban population. Lancet. 1997;350:829–833[CrossRef][Web of Science][Medline]
  12. Davies M, Hobbs F, Davis R, et al. Prevalence of left-ventricular systolic dysfunction and heart failure in the Echocardiographic Heart of England Screening study: a population based study. Lancet. 2001;358:439–444[CrossRef][Web of Science][Medline]
  13. Morgan S, Smith H, Simpson I, et al. Prevalence and clinical characteristics of left ventricular dysfunction among elderly patients in general practice setting: cross sectional survey. BMJ. 1999;318:368–372[Abstract/Free Full Text]
  14. Mosterd A, Hoes AW, de Bruyne MC, et al. Prevalence of heart failure and left ventricular dysfunction in the general population: The Rotterdam Study. Eur Heart J. 1999;20:447–455[Abstract/Free Full Text]
  15. Hedberg P, Lonnberg I, Jonason T, Nilsson G, Pehrsson K, Ringqvist I. Left ventricular systolic dysfunction in 75-year-old men and women; a population-based study. Eur Heart J. 2001;22:676–683[Abstract/Free Full Text]
  16. Schunkert H, Broeckel U, Hense HW, Keil U, Riegger GA. Left-ventricular dysfunction. [letter]Lancet. 1998;351:372[Web of Science][Medline]
  17. Gardin JM, Siscovick D, Anton-Culver H, et al. Sex, age, and disease affect echocardiographic left ventricular mass and systolic function in the free-living elderly. The Cardiovascular Health Study. Circulation. 1995;91:1739–1748[Abstract/Free Full Text]
  18. Kupari M, Lindroos M, Iivanainen AM, Heikkila J, Tilvis R. Congestive heart failure in old age: prevalence, mechanisms and 4-year prognosis in the Helsinki Ageing Study. J Intern Med. 1997;241:387–394[CrossRef][Web of Science][Medline]
  19. Devereux RB, Roman MJ, Paranicas M, et al. A population-based assessment of left ventricular systolic dysfunction in middle-aged and older adults: the Strong Heart Study. Am Heart J. 2001;141:439–446[CrossRef][Web of Science][Medline]
  20. Nielsen OW, Hilden J, Larsen CT, Hansen JF. Cross sectional study estimating prevalence of heart failure and left ventricular systolic dysfunction in community patients at risk. Heart. 2001;86:172–178[Abstract/Free Full Text]
  21. Cortina A, Reguero J, Segovia E, et al. Prevalence of heart failure in Asturias (a region in the north of Spain). Am J Cardiol. 2001;87:1417–1419[CrossRef][Web of Science][Medline]
  22. Kitzman DW, Gardin JM, Gottdiener JS, et al. Importance of heart failure with preserved systolic function in patients > or = 65 years of age. CHS Research Group. Cardiovascular Health Study. Am J Cardiol. 2001;87:413–419[CrossRef][Web of Science][Medline]
  23. Vasan RS, Larson MG, Benjamin EJ, Evans JC, Reiss CK, Levy D. Congestive heart failure in subjects with normal versus reduced left ventricular ejection fraction: prevalence and mortality in a population-based cohort. J Am Coll Cardiol. 1999;33:1948–1955[Abstract/Free Full Text]
  24. Senni M, Tribouilloy CM, Rodeheffer RJ, et al. Congestive heart failure in the community: a study of all incident cases in Olmsted County, Minnesota, in 1991. Circulation. 1998;98:2282–2289[Abstract/Free Full Text]
  25. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991;325:293–302[Abstract]
  26. MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet. 1999;353:2001–2009[CrossRef][Web of Science][Medline]
  27. Pitt B, Segal R, Martinez FA, et al. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet. 1997;349:747–752[CrossRef][Web of Science][Medline]
  28. CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med. 1987;316:1429–1435[Web of Science][Medline]
  29. Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med. 1997;336:525–533
  30. McMurray J. Heart failure: we need more trials in typical patients. Eur Heart J. 2000;21:699–700[Free Full Text]
  31. Petrie MC, Berry C, Stewart S, McMurray JJ. Failing ageing hearts. Eur Heart J. 2001;22:1978–1990[Free Full Text]
  32. Stewart S, MacIntyre K, MacLeod MM, Bailey AE, Capewell S, McMurray JJ. Trends in hospitalization for heart failure in Scotland, 1990–1996. An epidemic that has reached its peak? Eur Heart J. 2001;22:209–217[Abstract/Free Full Text]
  33. Haldeman GA, Croft JB, Giles WH, Rashidee A. Hospitalization of patients with heart failure: National Hospital Discharge Survey, 1985 to 1995. Am Heart J. 1999;137:352–360[CrossRef][Web of Science][Medline]
  34. Reitsma JB, Mosterd A, de Craen AJ, et al. Increase in hospital admission rates for heart failure in The Netherlands, 1980–1993. Heart. 1996;76:388–392[Abstract/Free Full Text]
  35. Stewart S, MacIntyre K, Hole DJ, Capewell S, McMurray JJ. More ‘malignant’ than cancer? Five-year survival following a first admission for heart failure. Eur J Heart Fail. 2001;3:315–322[Abstract/Free Full Text]
  36. MacIntyre K, Capewell S, Stewart S, et al. Evidence of improving prognosis in heart failure: trends in case fatality in 66 547 patients hospitalized between 1986 and 1995. Circulation. 2000;102:1126–1131[Abstract/Free Full Text]
  37. Fryback DG, Dasbach EJ, Klein R, et al. The Beaver Dam Health Outcomes Study: initial catalog of health-state quality factors. Med Decis Making. 1993;13:89–102
  38. Stewart AL, Greenfield S, Hays RD, et al. Functional status and well-being of patients with chronic conditions. Results from the Medical Outcomes Study. JAMA. 1989;262:907–913[Abstract/Free Full Text]
  39. Lewis EF, Johnson PA, Johnson W, Collins C, Griffin L, Stevenson LW. Preferences for quality of life or survival expressed by patients with heart failure. J Heart Lung Transplant. 2001;20:1016–1024[CrossRef][Web of Science][Medline]
  40. O'Connell JB, Bristow MR. Economic impact of heart failure in the United States: time for a different approach. J Heart Lung Transplant. 1994;13:S107–5112[Web of Science][Medline]
  41. McMurray J, McDonagh T, Morrison CE, Dargie HJ. Trends in hospitalization for heart failure in Scotland 1980–1990. Eur Heart J. 1993;14:1158–1162[Abstract/Free Full Text]
  42. Mosterd A, Reitsma JB, Grobbee DE. Angiotensin converting enzyme inhibition and hospitalisation rates for heart failure in the Netherlands, 1980 to 1999: the end of an epidemic? Heart. 2002;87:75–76[Free Full Text]
  43. Mejhert M, Persson H, Edner M, Kahan T. Epidemiology of heart failure in Sweden: a national survey. Eur J Heart Fail. 2001;3:97–103[CrossRef][Web of Science][Medline]
  44. McMurray JJ. Failure to practice evidence-based medicine: why do physicians not treat patients with heart failure with angiotensin-converting enzyme inhibitors? Eur Heart J. 1998;19(suppl L):L15–L21
  45. Remme WJ, Swedberg K. Guidelines for the diagnosis and treatment of chronic heart failure. Eur Heart J. 2001;22:1527–1560[Free Full Text]
  46. Hunt HA, Baker DW, Chin MH, et al. ACC/AHA Guidelines for the Evaluation and Management of Chronic Heart Failure in the Adult: Executive Summary. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1995 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the International Society for Heart and Lung Transplantation; endorsed by the Heart Failure Society of America. Circulation. 2001;104:2996–3007[Free Full Text]
  47. McMurray J, Cohen-Solal A, Dietz R, et al. Practical recommendations for the use of ACE inhibitors, beta-blockers and spironolactone in heart failure: putting guidelines into practice. Eur J Heart Fail. 2001;3:495–502[Abstract/Free Full Text]
  48. Blue L, Lang E, McMurray JJ, et al. Randomised controlled trial of specialist nurse intervention in heart failure. BMJ. 2001;323:715–718[Abstract/Free Full Text]
  49. Stewart S, Marley JE, Horowitz JD. Effects of a multidisciplinary, home-based intervention on unplanned readmissions and survival among patients with chronic congestive heart failure: a randomised controlled study. Lancet. 1999;354:1077–1083[CrossRef][Web of Science][Medline]
  50. Rodeheffer RJ, Jacobsen SJ, Gersh BJ, et al. The incidence and prevalence of congestive heart failure in Rochester, Minnesota. Mayo Clin Proc. 2nd Edition. 1993. p. 1143–1150
  51. Swedberg K, Pfeffer M, Granger C, et al. Candesartan in heart failure - assessment of reduction in mortality and morbidity (CHARM): rationale and design. CHARM-Programme Investigators. J Card Fail. 1999;5:276–282[CrossRef][Medline]
  52. Cleland JG, Tendera M, Adamus J, et al. Perindopril for elderly people with chronic heart failure: the PEP-CHF study. The PEP investigators. Eur J Heart Fail. 1999;1:211–217[CrossRef][Web of Science][Medline]
  53. Bonneux L, Barendregt JJ, Meeter K, Bonsel GJ, van der Maas PJ. Estimating clinical morbidity due to ischemic heart disease and congestive heart failure: the future rise of heart failure. Am J Public Health. 1994;84:20–28[Abstract/Free Full Text]
  54. Kelly DT. Paul Dudley White International Lecture. Our future society. A global challenge. Circulation. 1997;95:2459–2464[Free Full Text]
  55. Stewart S, MacIntyre K, Capewell S, McMurray JJV. Heart failure and the ageing population: an increasing burden in the 21st Century? Heart. 2002;: in press

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Postgrad. Med. J.Home page
J Amit Benjamin and K E Lewis
Sleep-disordered breathing and cardiovascular disease
Postgrad. Med. J., January 1, 2008; 84(987): 15 - 22.
[Abstract] [Full Text] [PDF]

Home page
 Eur J Heart FailHome page
M. H.L. van der Wal, T. Jaarsma, and D. J. van Veldhuisen
Non-compliance in patients with heart failure; how can we manage it?
Eur J Heart Fail, January 1, 2005; 7(1): 5 - 17.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
E. R. Perna, S. M. Macin, J. P. C. Canella, N. Augier, J. L. R. Stival, J. R. Cialzeta, A. E. Pitzus, E. H. Garcia, R. Obregon, M. Brizuela, et al.
Ongoing Myocardial Injury in Stable Severe Heart Failure: Value of Cardiac Troponin T Monitoring for High-Risk Patient Identification
Circulation, October 19, 2004; 110(16): 2376 - 2382.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Disclaimer
Right arrow Request Permissions
Google Scholar
Right arrow Articles by McMurray, J.J.V
Right arrow Articles by Stewart, S
Right arrow Search for Related Content
PubMed
Right arrow Articles by McMurray, J.J.V
Right arrow Articles by Stewart, S
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?